Shots:

• Exscientia to receive $100M up front & is eligible to receive ~$5.2B upon achievement of research, translational, clinical development, regulatory & commercial milestones & also get an option for clinical co-investment to increase the royalty ~21% on net sales of co-funded products
• The agreement will use Exscientia’s AI-based capabilities & personalized medicine platform to identify & select target projects along with the development of 15 new small molecule therapies for cancer & immune-mediated diseases
• Exscientia will lead the small molecule drug design & optimization activities. Sanofi will lead the preclinical/ clinical development, manufacturing & commercialization of the product

Ref: Businesswire | Image: Businesswire